Brain permeability of inhaled corticosteroids

被引:19
作者
Arya, V
Issar, M
Wang, YI
Talton, JD
Hochhaus, G
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, JHMHC, Gainesville, FL 32610 USA
[2] Nanotherapeut Inc, Alachua, FL 32615 USA
关键词
D O I
10.1211/jpp.57.9.0010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to evaluate if the permeability of inhaled corticosteroids entering the brain is reduced and if P-glycoprotein (P-gp) transporters are involved. Currently employed inhaled corticosteroids were given intravenously and intratracheally to rats at a dose of 100 mu g kg(-1). An ex-vivo receptor binding assay was used to monitor over 12 h the glucocorticoid receptor occupancy in the brain and a systemic reference organ (kidney). The involvement of P-gp in the brain permeability of triamcinolone acetonide was assessed in wild-type mice and mdr1a(-/-) knockout mice (mice lacking the gene for expressing P-gp). After both forms of administration, the average brain receptor occupancies were 20-56% of those of the reference organ, with the more lipophilic drugs showing a more pronounced receptor occupation. While the receptor occupancies in the liver of wild-type and mdr1a(-/-) mice were similar after administration of triamcinolone acetonide, brain receptor occupancies in mdr1a(-/-) mice were significantly greater (mdr1a(-/-): 47.6%, 40.2-55.0%, n = 2; wild-type: 11.5 +/- 33.0%, n = 3). Penetration into the brain for inhaled corticosteroids (especially those of lower lipophilicity) is reduced. Experiments in mdr1a(-/-) mice confirmed the involvement of P-gp transporters. Further studies are needed to assess whether potential drug interactions at the transporter level are of pharmacological significance.
引用
收藏
页码:1159 / 1167
页数:9
相关论文
共 21 条
[1]   GENERAL PRESENCE OF GLUCOCORTICOID RECEPTORS IN MAMMALIAN-TISSUES [J].
BALLARD, PL ;
BAXTER, JD ;
HIGGINS, SJ ;
ROUSSEAU, GG ;
TOMKINS, GM .
ENDOCRINOLOGY, 1974, 94 (04) :998-1002
[2]  
Buchwald P, 2004, PHARMAZIE, V59, P396
[3]   Mechanisms of clinically relevant drug interactions associated with tacrolimus [J].
Christians, U ;
Jacobsen, W ;
Benet, LZ ;
Lampen, A .
CLINICAL PHARMACOKINETICS, 2002, 41 (11) :813-851
[4]  
De Kloet ER, 1997, Stress, V2, P13
[5]   Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein [J].
Dilger, K ;
Schwab, M ;
Fromm, MF .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (05) :578-583
[6]   Glucocorticoid resistance in inflammatory bowel disease [J].
Farrell, RJ ;
Kelleher, D .
JOURNAL OF ENDOCRINOLOGY, 2003, 178 (03) :339-346
[7]   The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [J].
Greiner, B ;
Eichelbaum, M ;
Fritz, P ;
Kreichgauer, HP ;
Von Richter, O ;
Zundler, J ;
Kroemer, HK .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :147-153
[8]   ASSESSMENT OF GLUCOCORTICOID LUNG TARGETING BY EX-VIVO RECEPTOR-BINDING STUDIES IN RATS [J].
HOCHHAUS, G ;
GONZALEZROTHI, RJ ;
LUKYANOV, A ;
DERENDORF, H ;
SCHREIER, H ;
DALLACOSTA, T .
PHARMACEUTICAL RESEARCH, 1995, 12 (01) :134-137
[9]   Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain [J].
Karssen, AM ;
Meijer, OC ;
van der Sandt, ICJ ;
Lucassen, PJ ;
de Lange, ECM ;
de Boer, AG ;
de Kloet, ER .
ENDOCRINOLOGY, 2001, 142 (06) :2686-2694
[10]   The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone [J].
Karssen, AM ;
Meijer, OC ;
van der Sandt, ICJ ;
De Boer, AG ;
De Lange, ECM ;
De Kloet, ER .
JOURNAL OF ENDOCRINOLOGY, 2002, 175 (01) :251-260